<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01383720</url>
  </required_header>
  <id_info>
    <org_study_id>TP3659</org_study_id>
    <nct_id>NCT01383720</nct_id>
  </id_info>
  <brief_title>REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve SystEm</brief_title>
  <acronym>REPRISE I</acronym>
  <official_title>REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve SystEm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-arm feasibility study designed to assess the acute safety and
      performance of the Lotus Valve System for transcatheter aortic valve replacement in
      symptomatic patients with calcified aortic valve stenosis and who are at high risk for
      surgical intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence of aortic stenosis is increasing due to the aging of the world-wide population
      and the lack of drug therapies to prevent, halt, or effectively slow the stenotic process.
      Transcatheter aortic valve replacement has become a viable alternative for treatment of
      severe symptomatic aortic stenosis in selected patients who are unsuitable candidates for
      surgical valve replacement. The Lotus Valve System is designed to enable precise placement
      and minimize or eliminate the paravalvular regurgitation and associated adverse events seen
      with earlier generation devices. The REPRISE I study assesses acute safety and performance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">May 9, 2017</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Procedural Success</measure>
    <time_frame>Discharge or 7 days post-procedure, whichever comes first</time_frame>
    <description>Clinical procedural success defined as successful implantation of a Lotus Valve System (Device Success) without in-hospital Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) through discharge or 7 days post-procedure, whichever comes first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device Performance Endpoint-Repositioning</measure>
    <time_frame>procedure</time_frame>
    <description>Successful repositioning of the Lotus Valve System if repositioning is attempted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Performance Endpoint-Valve Retrieval, if Attempted</measure>
    <time_frame>procedure</time_frame>
    <description>Successful retrieval of the Lotus Valve System if retrieval is attempted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Aortic Regurgitation</measure>
    <time_frame>Discharge or 7 days post-procedure, whichever comes first</time_frame>
    <description>As determined by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paravalvular Aortic Regurgitation</measure>
    <time_frame>Discharge or 7 days post-procedure, whichever comes first</time_frame>
    <description>As determined by echocardiography</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Successful Access, Device Delivery, Deployment and Positioning and Retrieval of Delivery System</measure>
    <time_frame>Procedure</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Intended Performance of the Lotus Valve</measure>
    <time_frame>At time of discharge or 7 days post procedure</time_frame>
    <description>Aortic valve area &gt;1.0 cm2 plus either a mean aortic valve gradient &lt;20 mmHg or peak velocity &lt;3m/sec, without moderate or severe prosthetic valve aortic regurgitation</description>
  </other_outcome>
  <other_outcome>
    <measure>Single Valve Implanted in the Proper Anatomical Location</measure>
    <time_frame>procedure</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>No Major Adverse Cardiovascular and Cerebrovascular Events Through Discharge</measure>
    <time_frame>Discharge or 7 days post-procedure, whichever comes first</time_frame>
    <description>Major adverse cardiovascular or cerebrovascular events include all-cause mortality, periprocedural myocardial infarction ≤72 hours, major stroke, urgent/emergent conversion to surgery or repeat procedure for valve-related dysfunction</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Aortic Valve Gradient</measure>
    <time_frame>Discharge or 7 days post-procedure, whichever comes first</time_frame>
    <description>As determined by echocardiography</description>
  </other_outcome>
  <other_outcome>
    <measure>Aortic Valve Area</measure>
    <time_frame>Discharge or 7 days post-procedure, whichever comes first</time_frame>
    <description>As determined by echocardiography</description>
  </other_outcome>
  <other_outcome>
    <measure>Death</measure>
    <time_frame>Discharge or 7 days post-procedure, whichever comes first</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Peri-procedural Myocardial Infarction</measure>
    <time_frame>72 hours</time_frame>
    <description>Peri-Procedural Myocardial Infarction (≤72 hours after the index procedure)
New ischemic symptoms (e.g., chest pain or shortness of breath), or new ischemic signs (e.g. ventricular arrhythmias, new or worsening heart failure, new ST-segment changes, hemodynamic instability, or imaging evidence of new loss of viable myocardium or new wall motion abnormality), AND
Elevated cardiac biomarkers (preferably creatine kinase-myoglobin band) within 72 h after the index procedure, consisting of two or more post-procedure samples that are &gt; 0.6 to 8 h apart with a 20% increase in the second sample and a peak value exceeding 10X the 99th percentile upper reference limit (URL), or a peak value exceeding 5X the 99th percentile URL with new pathological Q waves in at least 2 contiguous leads</description>
  </other_outcome>
  <other_outcome>
    <measure>Major Stroke</measure>
    <time_frame>Discharge or 7 days post-procedure, whichever comes first</time_frame>
    <description>Confirmed with a Modified Rankin score &gt;/= 2 at 30 and 90 days</description>
  </other_outcome>
  <other_outcome>
    <measure>Urgent/Emergent Conversion to Surgery or Repeat Procedure for Valve-related Dysfunction</measure>
    <time_frame>Discharge or 7 days post-procedure, whichever comes first</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Major Vascular Complication</measure>
    <time_frame>Discharge or 7 days post-procedure, whichever comes first</time_frame>
    <description>Any thoracic aortic dissection
Access site or access-related vascular injury (dissection, stenosis, perforation, rupture, arterio-venous fistula, pseudoaneurysm, hematoma, irreversible nerve injury, or compartment syndrome) leading to either death, need for significant blood transfusions (≥4 units), unplanned percutaneous or surgical intervention, or irreversible end-organ damage (e.g. hypogastric artery occlusion causing visceral ischemia or spinal artery injury causing neurologic impairment)
Distal embolization (non-cerebral) from a vascular source requiring surgery or resulting in amputation or irreversible end-organ damage</description>
  </other_outcome>
  <other_outcome>
    <measure>New Conduction Disturbances or Arrhythmias Requiring Permanent Pacemaker</measure>
    <time_frame>Discharge or 7 days post-procedure, whichever comes first</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Bleeding</measure>
    <time_frame>Discharge or 7 days post-procedure, whichever comes first</time_frame>
    <description>Life-threatening or Disabling Bleeding
Fatal bleeding OR
Bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with compartment syndrome OR
Bleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery OR
Overt source of bleeding with drop in hemoglobin of ≥5 g/dL or whole blood or packed red blood cells (RBC) transfusion ≥4 units
Major Bleeding
Overt bleeding either associated with a drop in the hemoglobin level of at least 3.0g/dL or requiring transfusion of 2 or 3 units of whole blood/RBC AND
Does not meet criteria of life-threatening or disabling bleeding</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute Kidney Injury - Stage 2 or 3</measure>
    <time_frame>Discharge or 7 days post-procedure, whichever comes first</time_frame>
    <description>Stage 2: Increase in serum creatinine to 200-300% (2.0-3.0 times increase compared with baseline).
Stage 3: Increase in serum creatinine to ≥ 300% (&gt; 3 times increase compared with baseline) or serum creatinine of ≥ 4.0 mg/d (≥ 354 μmol/L) with an acute increase of at least 0.5 mg/dl (44 μmol/L). Subjects receiving renal replacement therapy are considered to meet Stage 3 criteria irrespective of other criteria.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Aortic Valve Calcification</condition>
  <condition>Aortic Valve Disease</condition>
  <arm_group>
    <arm_group_label>Lotus Valve System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lotus Valve System</intervention_name>
    <description>The Lotus Valve System includes the Lotus Valve, a bovine tissue tri-leaflet bioprosthetic aortic valve, and the Lotus Delivery Catheter for guidance and placement.</description>
    <arm_group_label>Lotus Valve System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient must be at least 70 years of age or older, and meets all of the criteria
             below.

          2. Patient has documented calcified native aortic valve stenosis, defined with an initial
             aortic valve area (AVA) of &lt;1.0 cm2 (or AVA index of &lt;0.6 cm2/m2), and a mean pressure
             gradient &gt;40 mmHg or a jet velocity &gt;4 m/s, as measured by echocardiography.

          3. The patient is considered at high risk for surgical aortic valve replacement with an
             STS (Society of Thoracic Surgeons) score ≥8% or a EuroSCORE ≥20%, or documented
             multidisciplinary heart team agreement that the patient is at high risk for surgery
             due to frailty and/or coexisting comorbidities.

          4. Symptomatic aortic valve stenosis with New York Heart Association (NYHA) Functional
             Class ≥ II.

          5. Patient has a documented aortic annulus size between 19 and 22 mm (able to accommodate
             the 23 mm Lotus™ Valve). Pre-procedure measurement by transthoracic echocardiography
             (TTE) is required. Other imaging modalities (e.g., transesophageal echocardiography
             (TEE), CT scan) can be used in an adjunctive manner.

          6. Patient (or legal representative) understands the trial requirements and the treatment
             procedures, and provides written informed consent.

          7. Patient agrees and is capable of returning to the study hospital for all required
             scheduled follow up visits.

        Exclusion Criteria:

          1. Patient has a congenital unicuspid or bicuspid aortic valve.

          2. Patient with an acute myocardial infarction (MI) within 30 days of the index procedure
             (defined as Q wave MI, or non-Q wave MI with total creatine kinase (CK) elevation ≥
             twice normal in the presence of CK-MB elevation and/or troponin level elevation (WHO
             definition)).

          3. Patient has had a cerebrovascular accident (CVA) or transient ischemic attack (TIA)
             within the past 6 months, or has any permanent neurologic defect prior to study
             enrollment.

          4. Patient is on dialysis or has serum creatinine level &gt;3.0 mg/dL.

          5. Patient has a pre-existing prosthetic heart valve (aortic or mitral) or a prosthetic
             ring in any position.

          6. Patient has &gt;2+ mitral regurgitation or &gt;2+ aortic regurgitation (ie., patient cannot
             have more than moderate mitral or aortic regurgitation).

          7. Moderate to severe pulmonary hypertension (PA systolic pressure &gt;60 mm Hg) as assessed
             by transthoracic echocardiography.

          8. Patient has a need for emergency surgery for any reason.

          9. Patient has a history of endocarditis within 12 months of index procedure or evidence
             of an active systemic infection or sepsis.

         10. Patient has echocardiographic evidence of intra-cardiac mass, thrombus or vegetation.

         11. Patient has Hgb &lt;9 g/dL, platelet count &lt;100,000 cells/mm3 or &gt;700,000 cells/mm3, and
             white blood cell (WBC) count &lt;3,000 cells/mm3.

         12. Patient is receiving chronic (≥72 hours) anticoagulation therapy (e.g., heparin,
             warfarin) and who cannot tolerate concomitant therapy with aspirin and clopidogrel
             (patients who require chronic anticoagulation must be treated with either aspirin or
             clopidogrel).

         13. Patient has active peptic ulcer disease, gastrointestinal (GI) bleed within the past 3
             months, other bleeding diathesis or coagulopathy or will refuse transfusions.

         14. Patient is contraindicated for transesophageal echocardiography (TEE).

         15. Patient has known hypersensitivity to contrast agents that cannot be adequately
             pre-medicated, or has known hypersensitivity to aspirin, all thienopyridines, heparin,
             nickel, titanium, or polyurethanes.

         16. Patient has a life expectancy of less than 12 months due to non-cardiac, co-morbid
             conditions based on the assessment of the investigator at the time of enrollment.

         17. Patient has other cardiac devices or hardware with which the study device will
             interfere with device placement (per physician judgment).

         18. Patient has hypertrophic obstructive cardiomyopathy.

         19. Patient has any therapeutic invasive cardiac procedure within 30 days prior to the
             index procedure.

         20. Untreated clinically significant coronary artery disease requiring revascularization.

         21. Patient has documented left ventricular ejection fraction (LVEF) &lt;30%.

         22. Patient is in cardiogenic shock or has hemodynamic instability requiring inotropic
             support or mechanical support devices.

         23. Patient has severe peripheral vascular disease (including aneurysm defined as maximal
             luminal diameter &gt;5cm or with documented presence of thrombus, marked tortuosity,
             narrowing of the abdominal aorta, severe unfolding of the thoracic aorta or thick
             (&gt;5mm), protruding or ulcerated atheroma in the aortic arch) or symptomatic carotid or
             vertebral disease.

         24. Patient has a femoral artery lumen of &lt;6.0 mm or severe iliofemoral tortuosity or
             calcification that would prevent safe placement of the introducer sheath.

         25. Current problems with substance abuse (e.g. alcohol, cocaine, heroin, etc).

         26. Patient is participating in another investigational drug or device study that has not
             reached its primary endpoint.

         27. Patient has preexisting untreated conduction system disorders: Type II second-degree
             atrioventricular (AV) block, bifascicular or trifascicular block.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian Meredith, MBBS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern Health, Monash Medical Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3040</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Health Monash Medical Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2011</study_first_submitted>
  <study_first_submitted_qc>June 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2011</study_first_posted>
  <results_first_submitted>April 16, 2013</results_first_submitted>
  <results_first_submitted_qc>May 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 9, 2016</results_first_posted>
  <last_update_submitted>May 23, 2017</last_update_submitted>
  <last_update_submitted_qc>May 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Valve Stenosis</keyword>
  <keyword>Transcatheter Aortic Valve Replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcinosis</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to make individual participant data (IPD) available.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were identified by their physicians as meeting the study inclusion/exclusion criteria.</recruitment_details>
      <pre_assignment_details>Screening materials from patients identified by the investigators as having met the inclusion and exclusion criteria were reviewed by a Case Review Committee to assess and confirm eligibility.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lotus Valve System</title>
          <description>Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Primary Endpoint (Discharge/7 Days)</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11">Study is continuing to 5 years. All patients are still in the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lotus Valve System</title>
          <description>Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.0" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>General Medical History</title>
          <description>The same participant may be included in more than one category therefore the number of participants for this baseline measure does not equal the total number of participants in the group.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Diabetes mellitus (current)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperlipidemia (medically treated)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension (medically treated)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of peripheral vascular disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dialysis dependent renal failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic obstructive pulmonary disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac History</title>
          <description>The same participant may be included in more than one category therefore the number of participants for this baseline measure does not equal the total number of participants in the group.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Coronary artery disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previous percutaneous coronary intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previous coronary artery bypass graft surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of atrial fibrillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New York Heart Association Class</title>
          <description>New York Heart Association (NYHA) functional classification system relates symptoms to everyday activities and the patient's quality of life.
Class I (Mild): No limitation of physical activity. Class II (Mild): Slight limitation of physical activity. Class III (Moderate): Marked limitation of physical activity. Class IV (Severe): Unable to carry out any physical activity without discomfort.
Symptomatic aortic valve stenosis is related to NYHA Functional Class ≥ II.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Class I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Modified Rankin Scale</title>
          <description>Higher score equals a worse condition with zero meaning no symptoms, 2 meaning slight disability and 6 meaning death.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 or higher</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Neurological History</title>
          <description>A patient may or may not belong to a category or may belong to more than one category. Therefore the sum may not equal the overall number of patients in the study.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Transient Ischemic Attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cerebrovascular Accident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aortic valve area (effective orifice area)</title>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.68" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Aortic Valve Gradient</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.9" spread="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Ventricular Ejection Fraction</title>
          <description>This measure represents the percent of Left Ventricular Ejection Fraction.</description>
          <units>percent of LVEF</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.3" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aortic regurgitation (moderate or severe)</title>
          <description>A patient may or may not belong to a category or may belong to more than one category. Therefore the sum may not equal the overall number of patients in the study.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mitral Regurgitation (moderate or severe)</title>
          <description>A patient may or may not belong to a category or may belong to more than one category. Therefore the sum may not equal the overall number of patients in the study.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.6" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Albumin</title>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.9" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>5-Meter Gait Speed</title>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.2" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maximum Grip Strength Average</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.3" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Katz Index</title>
          <description>Katz Index of Independence in Activities of Daily Living (ADL) is an instrument to assess functional status as a measurement of the client’s ability to perform activities of daily living independently.
The Index ranks adequacy of performance in the six functions of bathing, dressing, toileting, transferring, continence, and feeding. A score of 6 indicates full function, 4 indicates moderate impairment, and 2 or less indicates severe functional impairment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.9" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mini-Cognitive Assessment for Dementia</title>
          <description>Mini-Cognitive Assessment for Dementia scores range from 5 (normal cognition) to 0 (impaired cognition).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.3" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Charlson Comorbidity Index Score</title>
          <description>Charlson Comorbidity Index contains 19 categories of comorbidity and assigns a weighted value to each subject’s comorbidity based on the risk of 1-year mortality.
A score of 0 reflects no comorbidities and 19 reveals severe comorbidities.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.8" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Society of Thoracic Surgeons (STS) Score</title>
          <description>The Society of Thoracic Surgeons’ risk models predict the risk of operative mortality and morbidity after adult cardiac surgery on the basis of patient demographic and clinical variables. The patient is considered at high risk for surgical aortic valve replacement with an STS score ≥8% or a EuroSCORE ≥20%, or documented multidisciplinary heart team agreement that the patient is at high risk for surgery due to frailty and/or coexisting comorbidities. For example, an STS score of 10% means predicted operative mortality or serious, irreversible morbidity risk of 10% at 30 days.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.9" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EuroScore</title>
          <description>European System for Cardiac Operative Risk Evaluation. EuroSCORE is a method of calculating predicted operative mortality for patients undergoing cardiac surgery.
The patient is considered at high risk for surgical aortic valve replacement with an STS score ≥8% or a EuroSCORE ≥20%, or documented multidisciplinary heart team agreement that the patient is at high risk for surgery due to frailty and/or coexisting comorbidities. EuroScore II is a risk model that calculates the risk of death after a heart operation through 30 days.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.5" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Procedural Success</title>
        <description>Clinical procedural success defined as successful implantation of a Lotus Valve System (Device Success) without in-hospital Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) through discharge or 7 days post-procedure, whichever comes first.</description>
        <time_frame>Discharge or 7 days post-procedure, whichever comes first</time_frame>
        <population>Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis</population>
        <group_list>
          <group group_id="O1">
            <title>Lotus Valve System</title>
            <description>Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Procedural Success</title>
          <description>Clinical procedural success defined as successful implantation of a Lotus Valve System (Device Success) without in-hospital Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) through discharge or 7 days post-procedure, whichever comes first.</description>
          <population>Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device Performance Endpoint-Repositioning</title>
        <description>Successful repositioning of the Lotus Valve System if repositioning is attempted</description>
        <time_frame>procedure</time_frame>
        <population>Patients in whom repositioning of the Lotus Valve was attempted</population>
        <group_list>
          <group group_id="O1">
            <title>Lotus Valve System</title>
            <description>Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis</description>
          </group>
        </group_list>
        <measure>
          <title>Device Performance Endpoint-Repositioning</title>
          <description>Successful repositioning of the Lotus Valve System if repositioning is attempted</description>
          <population>Patients in whom repositioning of the Lotus Valve was attempted</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device Performance Endpoint-Valve Retrieval, if Attempted</title>
        <description>Successful retrieval of the Lotus Valve System if retrieval is attempted</description>
        <time_frame>procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lotus Valve System</title>
            <description>Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis</description>
          </group>
        </group_list>
        <measure>
          <title>Device Performance Endpoint-Valve Retrieval, if Attempted</title>
          <description>Successful retrieval of the Lotus Valve System if retrieval is attempted</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There were no attempts made to retrieve the valve.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Central Aortic Regurgitation</title>
        <description>As determined by echocardiography</description>
        <time_frame>Discharge or 7 days post-procedure, whichever comes first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lotus Valve System</title>
            <description>Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis</description>
          </group>
        </group_list>
        <measure>
          <title>Central Aortic Regurgitation</title>
          <description>As determined by echocardiography</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trivial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate or Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Paravalvular Aortic Regurgitation</title>
        <description>As determined by echocardiography</description>
        <time_frame>Discharge or 7 days post-procedure, whichever comes first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lotus Valve System</title>
            <description>Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis</description>
          </group>
        </group_list>
        <measure>
          <title>Paravalvular Aortic Regurgitation</title>
          <description>As determined by echocardiography</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trivial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate or Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Successful Access, Device Delivery, Deployment and Positioning and Retrieval of Delivery System</title>
        <time_frame>Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lotus Valve System</title>
            <description>Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis</description>
          </group>
        </group_list>
        <measure>
          <title>Successful Access, Device Delivery, Deployment and Positioning and Retrieval of Delivery System</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Intended Performance of the Lotus Valve</title>
        <description>Aortic valve area &gt;1.0 cm2 plus either a mean aortic valve gradient &lt;20 mmHg or peak velocity &lt;3m/sec, without moderate or severe prosthetic valve aortic regurgitation</description>
        <time_frame>At time of discharge or 7 days post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lotus Valve System</title>
            <description>Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis</description>
          </group>
        </group_list>
        <measure>
          <title>Intended Performance of the Lotus Valve</title>
          <description>Aortic valve area &gt;1.0 cm2 plus either a mean aortic valve gradient &lt;20 mmHg or peak velocity &lt;3m/sec, without moderate or severe prosthetic valve aortic regurgitation</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Single Valve Implanted in the Proper Anatomical Location</title>
        <time_frame>procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lotus Valve System</title>
            <description>Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis</description>
          </group>
        </group_list>
        <measure>
          <title>Single Valve Implanted in the Proper Anatomical Location</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>No Major Adverse Cardiovascular and Cerebrovascular Events Through Discharge</title>
        <description>Major adverse cardiovascular or cerebrovascular events include all-cause mortality, periprocedural myocardial infarction ≤72 hours, major stroke, urgent/emergent conversion to surgery or repeat procedure for valve-related dysfunction</description>
        <time_frame>Discharge or 7 days post-procedure, whichever comes first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lotus Valve System</title>
            <description>Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis</description>
          </group>
        </group_list>
        <measure>
          <title>No Major Adverse Cardiovascular and Cerebrovascular Events Through Discharge</title>
          <description>Major adverse cardiovascular or cerebrovascular events include all-cause mortality, periprocedural myocardial infarction ≤72 hours, major stroke, urgent/emergent conversion to surgery or repeat procedure for valve-related dysfunction</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Aortic Valve Gradient</title>
        <description>As determined by echocardiography</description>
        <time_frame>Discharge or 7 days post-procedure, whichever comes first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lotus Valve System</title>
            <description>Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Aortic Valve Gradient</title>
          <description>As determined by echocardiography</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Aortic Valve Area</title>
        <description>As determined by echocardiography</description>
        <time_frame>Discharge or 7 days post-procedure, whichever comes first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lotus Valve System</title>
            <description>Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis</description>
          </group>
        </group_list>
        <measure>
          <title>Aortic Valve Area</title>
          <description>As determined by echocardiography</description>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Death</title>
        <time_frame>Discharge or 7 days post-procedure, whichever comes first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lotus Valve System</title>
            <description>Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis</description>
          </group>
        </group_list>
        <measure>
          <title>Death</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Peri-procedural Myocardial Infarction</title>
        <description>Peri-Procedural Myocardial Infarction (≤72 hours after the index procedure)
New ischemic symptoms (e.g., chest pain or shortness of breath), or new ischemic signs (e.g. ventricular arrhythmias, new or worsening heart failure, new ST-segment changes, hemodynamic instability, or imaging evidence of new loss of viable myocardium or new wall motion abnormality), AND
Elevated cardiac biomarkers (preferably creatine kinase-myoglobin band) within 72 h after the index procedure, consisting of two or more post-procedure samples that are &gt; 0.6 to 8 h apart with a 20% increase in the second sample and a peak value exceeding 10X the 99th percentile upper reference limit (URL), or a peak value exceeding 5X the 99th percentile URL with new pathological Q waves in at least 2 contiguous leads</description>
        <time_frame>72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lotus Valve System</title>
            <description>Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis</description>
          </group>
        </group_list>
        <measure>
          <title>Peri-procedural Myocardial Infarction</title>
          <description>Peri-Procedural Myocardial Infarction (≤72 hours after the index procedure)
New ischemic symptoms (e.g., chest pain or shortness of breath), or new ischemic signs (e.g. ventricular arrhythmias, new or worsening heart failure, new ST-segment changes, hemodynamic instability, or imaging evidence of new loss of viable myocardium or new wall motion abnormality), AND
Elevated cardiac biomarkers (preferably creatine kinase-myoglobin band) within 72 h after the index procedure, consisting of two or more post-procedure samples that are &gt; 0.6 to 8 h apart with a 20% increase in the second sample and a peak value exceeding 10X the 99th percentile upper reference limit (URL), or a peak value exceeding 5X the 99th percentile URL with new pathological Q waves in at least 2 contiguous leads</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Major Stroke</title>
        <description>Confirmed with a Modified Rankin score &gt;/= 2 at 30 and 90 days</description>
        <time_frame>Discharge or 7 days post-procedure, whichever comes first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lotus Valve System</title>
            <description>Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis</description>
          </group>
        </group_list>
        <measure>
          <title>Major Stroke</title>
          <description>Confirmed with a Modified Rankin score &gt;/= 2 at 30 and 90 days</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Urgent/Emergent Conversion to Surgery or Repeat Procedure for Valve-related Dysfunction</title>
        <time_frame>Discharge or 7 days post-procedure, whichever comes first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lotus Valve System</title>
            <description>Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis</description>
          </group>
        </group_list>
        <measure>
          <title>Urgent/Emergent Conversion to Surgery or Repeat Procedure for Valve-related Dysfunction</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Major Vascular Complication</title>
        <description>Any thoracic aortic dissection
Access site or access-related vascular injury (dissection, stenosis, perforation, rupture, arterio-venous fistula, pseudoaneurysm, hematoma, irreversible nerve injury, or compartment syndrome) leading to either death, need for significant blood transfusions (≥4 units), unplanned percutaneous or surgical intervention, or irreversible end-organ damage (e.g. hypogastric artery occlusion causing visceral ischemia or spinal artery injury causing neurologic impairment)
Distal embolization (non-cerebral) from a vascular source requiring surgery or resulting in amputation or irreversible end-organ damage</description>
        <time_frame>Discharge or 7 days post-procedure, whichever comes first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lotus Valve System</title>
            <description>Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis</description>
          </group>
        </group_list>
        <measure>
          <title>Major Vascular Complication</title>
          <description>Any thoracic aortic dissection
Access site or access-related vascular injury (dissection, stenosis, perforation, rupture, arterio-venous fistula, pseudoaneurysm, hematoma, irreversible nerve injury, or compartment syndrome) leading to either death, need for significant blood transfusions (≥4 units), unplanned percutaneous or surgical intervention, or irreversible end-organ damage (e.g. hypogastric artery occlusion causing visceral ischemia or spinal artery injury causing neurologic impairment)
Distal embolization (non-cerebral) from a vascular source requiring surgery or resulting in amputation or irreversible end-organ damage</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>New Conduction Disturbances or Arrhythmias Requiring Permanent Pacemaker</title>
        <time_frame>Discharge or 7 days post-procedure, whichever comes first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lotus Valve System</title>
            <description>Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis</description>
          </group>
        </group_list>
        <measure>
          <title>New Conduction Disturbances or Arrhythmias Requiring Permanent Pacemaker</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Bleeding</title>
        <description>Life-threatening or Disabling Bleeding
Fatal bleeding OR
Bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with compartment syndrome OR
Bleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery OR
Overt source of bleeding with drop in hemoglobin of ≥5 g/dL or whole blood or packed red blood cells (RBC) transfusion ≥4 units
Major Bleeding
Overt bleeding either associated with a drop in the hemoglobin level of at least 3.0g/dL or requiring transfusion of 2 or 3 units of whole blood/RBC AND
Does not meet criteria of life-threatening or disabling bleeding</description>
        <time_frame>Discharge or 7 days post-procedure, whichever comes first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lotus Valve System</title>
            <description>Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding</title>
          <description>Life-threatening or Disabling Bleeding
Fatal bleeding OR
Bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with compartment syndrome OR
Bleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery OR
Overt source of bleeding with drop in hemoglobin of ≥5 g/dL or whole blood or packed red blood cells (RBC) transfusion ≥4 units
Major Bleeding
Overt bleeding either associated with a drop in the hemoglobin level of at least 3.0g/dL or requiring transfusion of 2 or 3 units of whole blood/RBC AND
Does not meet criteria of life-threatening or disabling bleeding</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Life-threatening or disabling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Acute Kidney Injury - Stage 2 or 3</title>
        <description>Stage 2: Increase in serum creatinine to 200-300% (2.0-3.0 times increase compared with baseline).
Stage 3: Increase in serum creatinine to ≥ 300% (&gt; 3 times increase compared with baseline) or serum creatinine of ≥ 4.0 mg/d (≥ 354 μmol/L) with an acute increase of at least 0.5 mg/dl (44 μmol/L). Subjects receiving renal replacement therapy are considered to meet Stage 3 criteria irrespective of other criteria.</description>
        <time_frame>Discharge or 7 days post-procedure, whichever comes first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lotus Valve System</title>
            <description>Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Kidney Injury - Stage 2 or 3</title>
          <description>Stage 2: Increase in serum creatinine to 200-300% (2.0-3.0 times increase compared with baseline).
Stage 3: Increase in serum creatinine to ≥ 300% (&gt; 3 times increase compared with baseline) or serum creatinine of ≥ 4.0 mg/d (≥ 354 μmol/L) with an acute increase of at least 0.5 mg/dl (44 μmol/L). Subjects receiving renal replacement therapy are considered to meet Stage 3 criteria irrespective of other criteria.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>After 1 year index procedure</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lotus Valve System</title>
          <description>Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Secretion discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Peripheral artery dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Principal Investigator (PI) shall have the right to publish the results, provided that before publishing, the PI shall submit copies of any proposed publication or presentation to the Sponsor for review at least 45 days in advance of submission for publication or presentation to a publisher or other third party. Sponsor reserves the right to delete any confidential information or other proprietary information of Sponsor from the proposed publication or presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials, Valves</name_or_title>
      <organization>Boston Scientific Corporation</organization>
      <phone>408-370-1550</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

